PleoPharma Receives $6.5 Million Grant for Cannabis Withdrawal Treatment Trial

PleoPharma Makes Headlines with $6.5 Million Grant

In a significant move towards addressing cannabis addiction challenges, PleoPharma, Inc. has announced a generous grant of $6.5 million from the National Institute on Drug Abuse (NIDA). This funding is aimed at advancing their pivotal clinical program for PP-01, a novel investigational treatment focused on alleviating cannabis withdrawal symptoms in adults grappling with cannabis use disorder (CUD).

According to data from the Substance Abuse and Mental Health Services Administration (SAMHSA), over 19 million U.S. adults are affected by CUD. Withdrawal symptoms such as anxiety, irritability, sleep disturbances, and cravings often impede recovery and increase the likelihood of relapse. Despite the widespread impact of this disorder, effective pharmacological treatments remain unavailable, emphasizing the urgent need for innovation in this field.

Dr. Shelli Grahm, senior vice president of medical and clinical research at PleoPharma, acknowledged the importance of this NIDA award as a validation of the significant unmet need for effective treatment options regarding cannabis use disorder. She expressed optimism that PP-01 could play a vital role in mitigating withdrawal symptoms that hinder recovery efforts.

The clinical development of PP-01 follows promising results from earlier phases of trials. PleoPharma successfully completed Phase 1 and Phase 2b studies, with the latter having conclusively demonstrated its efficacy in reducing withdrawal symptoms without serious adverse effects. The Fast Track designation granted by the U.S. Food and Drug Administration (FDA) highlights the pressing need for effective interventions for cannabis dependence.

Now, as PleoPharma embarks on its Phase 3 CAN-004 trial, they have initiated the enrollment and dosing of adult participants characterized by moderate to severe cannabis use disorder. This trial represents a crucial step towards gathering the clinical evidence needed for potential FDA approval.

PleoPharma’s CEO, Ginger Constantine, reinforced their commitment to addressing the needs of individuals suffering from cannabis addiction, emphasizing the importance of ensuring they receive the same level of scientific rigor and medical care as those with other substance use disorders. The support from NIDA amplifies their mission to introduce a medication-assisted treatment option that can help patients stay engaged in their recovery journey.

PP-01 is designed as a once-daily oral treatment with a rapidly onset of action, targeting the dysregulation of neurotransmitters in the mesolimbic reward pathway. As a first-in-class therapeutic approach, it aims to manage the withdrawal symptoms faced by many individuals battling cannabis dependence.

Founded on the principles of innovative addiction medicine, PleoPharma aims to address the growing need for effective treatments for cannabis-related health issues. The organization prides itself on a highly experienced team with an impressive track record of successful product launches and rigorous medical research.

As the CAN-004 trial progresses, the medical community and stakeholders hope that the research supported by NIDA will lead to significant advancements in the treatment of cannabis use disorder, thereby helping millions reclaim their lives from addiction.